Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Heart patch could revolutionize home monitoring for heart failure patients

NCT ID NCT06243029

Knowledge-focused Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a wearable heart monitoring patch in people recovering from a severe heart failure episode. The goal was to see if the patch could collect useful health data at home, making future drug research easier. About 54 adults wore the patch for a few days after leaving the hospital and again 6-8 weeks later. The study did not provide treatment, but aimed to improve how we measure recovery.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

54 people

The number who actually took part.

Started

Jan 2024

Finished

Mar 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Potential study participants will be identified through review of hospital inpatient lists, conversations with healthcare providers and review of medical notes. Participants who meet the study eligibility criteria will be approached whilst still in the hospital but due to be discharged by the research team who will enquire whether they are interested in participating in the study. Up to 80 male and female participants over 18 years old will be enrolled in the study.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Men and women aged 18 years or older * Confirmed diagnosis of heart failure according to the latest ESC criteria * Primary cause of hospitalisation due to decompensated heart failure * Willing and able to complete all visits and assessments as per protocol * Provision of signed and dated, written informed consent before any study-specific procedures. Exclusion Criteria: * Receiving renal replacement therapy * Implanted cardiac (or other) device in-situ, cardiac pacemaker, defibrillator, or other implanted electronic devices or other ventricular assist device in situ * Currently receiving chemotherapy * Receiving end-of-life care * Active severe infection: individuals with an active severe infection, as determined by the PI's clinical judgment, will not be eligible for study participation * Hypersensitivity to patch adhesive/ materials in the patch * Skin condition or damage that prevents wearing of the patch.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute decompensated heart failure are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

congestive heart failure heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute decompensated heart failure

Contacts and locations

Locations

  • Research Site

    Cambridge, CB2 0QQ, United Kingdom

  • Research Site

    Harefield, UB9 6JH, United Kingdom

  • Research Site

    Leicester, LE3 9PQ, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.